CR20220308A - Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso - Google Patents
Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de usoInfo
- Publication number
- CR20220308A CR20220308A CR20220308A CR20220308A CR20220308A CR 20220308 A CR20220308 A CR 20220308A CR 20220308 A CR20220308 A CR 20220308A CR 20220308 A CR20220308 A CR 20220308A CR 20220308 A CR20220308 A CR 20220308A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- delta
- methods
- heterocyclic compounds
- desaturase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939821P | 2019-11-25 | 2019-11-25 | |
| PCT/US2020/062020 WO2021108408A1 (en) | 2019-11-25 | 2020-11-24 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220308A true CR20220308A (es) | 2022-08-04 |
Family
ID=73855555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220308A CR20220308A (es) | 2019-11-25 | 2020-11-24 | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11512097B2 (https=) |
| EP (1) | EP4065223A1 (https=) |
| JP (2) | JP7254246B2 (https=) |
| KR (2) | KR102598203B1 (https=) |
| CN (2) | CN114728167B (https=) |
| AR (1) | AR120556A1 (https=) |
| AU (1) | AU2020392087B2 (https=) |
| BR (1) | BR112022010054A2 (https=) |
| CA (1) | CA3162281A1 (https=) |
| CL (2) | CL2022001357A1 (https=) |
| CO (1) | CO2022008690A2 (https=) |
| CR (1) | CR20220308A (https=) |
| IL (1) | IL293191B2 (https=) |
| JO (1) | JOP20220125A1 (https=) |
| MX (1) | MX2022006281A (https=) |
| PE (1) | PE20231097A1 (https=) |
| PH (1) | PH12022551282A1 (https=) |
| SA (1) | SA522432710B1 (https=) |
| TW (2) | TWI867822B (https=) |
| UY (1) | UY38971A (https=) |
| WO (1) | WO2021108408A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11220510B2 (en) * | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| KR102598203B1 (ko) | 2019-11-25 | 2023-11-03 | 암젠 인크 | 델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법 |
| CN115557903A (zh) * | 2022-09-27 | 2023-01-03 | 山东潍坊润丰化工股份有限公司 | 一种特草定的制备方法 |
| WO2024112763A1 (en) | 2022-11-23 | 2024-05-30 | Amgen Inc. | Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3130633A1 (de) | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
| EP0242690B1 (en) | 1986-04-07 | 1993-06-30 | Kumiai Chemical Industry Co., Ltd. | 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same |
| IL130181A0 (en) | 1996-12-05 | 2000-06-01 | Amgen Inc | Substituted pyrimidone and pyridone compounds and methods of use |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6537998B1 (en) * | 1999-10-15 | 2003-03-25 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| DE60022769T2 (de) | 1999-10-15 | 2006-07-06 | Neurocrine Biosciences, Inc., San Diego | Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen |
| AU2003238157A1 (en) | 2002-06-18 | 2003-12-31 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| JP2004107228A (ja) | 2002-09-17 | 2004-04-08 | Nippon Nohyaku Co Ltd | 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤 |
| PE20051089A1 (es) | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| AU2005317928B2 (en) | 2004-12-24 | 2010-06-10 | Astrazeneca Ab | Heterocyclic compounds as CCR2b antagonists |
| CA2612585A1 (en) | 2005-06-27 | 2007-01-04 | Amgen Inc. | Anti-inflammatory aryl nitrile compounds |
| WO2007027012A1 (en) | 2005-07-18 | 2007-03-08 | Samsung Electronics Co., Ltd. | Video coding method and apparatus for reducing mismatch between encoder and decoder |
| BRPI0614158A2 (pt) | 2005-07-27 | 2016-11-22 | Basf Ag | compostos, processo para reparar compostos, agente fungicida, semente, e, processo para combater fungos nocivos fitopatogênicos |
| EP1915376B1 (de) | 2005-07-27 | 2009-09-09 | Basf Se | Fungizide 6-phenyl-pyrazolopyrimidin-7-ylamine |
| AU2006274075A1 (en) | 2005-07-27 | 2007-02-01 | Basf Se | Fungicide 6-phenyl-triazolopyrimidinyl amines |
| US20070082900A1 (en) | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| EP2074127A1 (en) | 2006-09-28 | 2009-07-01 | Novartis AG | Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use |
| CN101522676A (zh) | 2006-10-05 | 2009-09-02 | Cv医药有限公司 | 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物 |
| WO2008057601A2 (en) | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| AU2008206921B2 (en) | 2007-01-19 | 2012-11-01 | Basf Se | Fungicidal mixtures of 1-methylpyrazole-4-ylcarboxylic acid anilides and azolopyrimidinylamines |
| EP2131658A2 (en) | 2007-01-30 | 2009-12-16 | Basf Se | Method for improving plant health |
| BRPI0809045A2 (pt) | 2007-03-23 | 2014-09-02 | Basf Se | Combinações de substância ativa, uso de combinações de substância ativa, métodos para combater fungos fitopatogênicos indesejáveis, para preparar agentes pesticidas, e para tratar sementes, e, produto de revestimento de semente |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CA2719362A1 (en) * | 2008-04-04 | 2009-10-08 | Gilead Sciences, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| US20100099561A1 (en) | 2008-10-15 | 2010-04-22 | E.I. Du Pont De Nemours And Company | Heterobicyclic alkylthio-bridged isoxazolines |
| AR075158A1 (es) | 2009-01-27 | 2011-03-16 | Takeda Pharmaceutical | Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos. |
| CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| WO2011114148A1 (en) * | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| WO2012011592A1 (ja) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2013177538A2 (en) | 2012-05-24 | 2013-11-28 | Colorado State University Research Foundation | Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease |
| WO2014139326A1 (en) | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| MX2016002794A (es) | 2013-09-05 | 2016-09-13 | Genentech Inc | Compuestos antiproliferativos. |
| WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| WO2015135094A1 (en) | 2014-03-13 | 2015-09-17 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| BR112016024455B1 (pt) | 2014-04-23 | 2023-02-07 | Mitsubishi Tanabe Pharma Corporation | Composto heterocíclico bicíclico ou tricíclico |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| JP6791717B2 (ja) | 2015-10-22 | 2020-11-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP2017091808A (ja) | 2015-11-10 | 2017-05-25 | 株式会社フジクラ | 酸化物超電導線材の製造方法及び超電導コイルの製造方法 |
| US11414385B2 (en) | 2015-12-21 | 2022-08-16 | The University Of Chicago | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases |
| CR20190157A (es) | 2016-08-31 | 2019-08-13 | Agios Pharmaceuticals Inc | Inhibidores de procesos metabólicos celulares |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| CN106749271B (zh) | 2016-12-07 | 2019-04-05 | 青岛科技大学 | 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途 |
| SG11201910197SA (en) | 2017-05-15 | 2019-11-28 | Dana Farber Cancer Inst Inc | Compounds for treating dengue virus infection and other viral infections |
| WO2018229683A1 (en) | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| MX2020002869A (es) | 2017-09-15 | 2020-07-24 | Aduro Biotech Inc | Compuestos de pirazolopirimidinona y usos de los mismos. |
| KR102598203B1 (ko) * | 2019-11-25 | 2023-11-03 | 암젠 인크 | 델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법 |
-
2020
- 2020-11-24 KR KR1020227021152A patent/KR102598203B1/ko active Active
- 2020-11-24 CR CR20220308A patent/CR20220308A/es unknown
- 2020-11-24 PE PE2022000849A patent/PE20231097A1/es unknown
- 2020-11-24 AU AU2020392087A patent/AU2020392087B2/en active Active
- 2020-11-24 EP EP20828193.1A patent/EP4065223A1/en active Pending
- 2020-11-24 CN CN202080081465.8A patent/CN114728167B/zh active Active
- 2020-11-24 US US17/103,389 patent/US11512097B2/en active Active
- 2020-11-24 IL IL293191A patent/IL293191B2/en unknown
- 2020-11-24 CN CN202410291075.3A patent/CN118161500A/zh active Pending
- 2020-11-24 MX MX2022006281A patent/MX2022006281A/es unknown
- 2020-11-24 WO PCT/US2020/062020 patent/WO2021108408A1/en not_active Ceased
- 2020-11-24 BR BR112022010054A patent/BR112022010054A2/pt unknown
- 2020-11-24 KR KR1020237037455A patent/KR20230154292A/ko not_active Ceased
- 2020-11-24 PH PH1/2022/551282A patent/PH12022551282A1/en unknown
- 2020-11-24 JP JP2022529556A patent/JP7254246B2/ja active Active
- 2020-11-24 CA CA3162281A patent/CA3162281A1/en active Pending
- 2020-11-25 UY UY0001038971A patent/UY38971A/es not_active Application Discontinuation
- 2020-11-25 TW TW112142068A patent/TWI867822B/zh active
- 2020-11-25 AR ARP200103274A patent/AR120556A1/es unknown
- 2020-11-25 TW TW109141315A patent/TWI815061B/zh active
-
2021
- 2021-03-16 US US17/203,457 patent/US20210221824A1/en not_active Abandoned
-
2022
- 2022-05-23 JO JOP/2022/0125A patent/JOP20220125A1/ar unknown
- 2022-05-24 SA SA522432710A patent/SA522432710B1/ar unknown
- 2022-05-24 CL CL2022001357A patent/CL2022001357A1/es unknown
- 2022-06-22 CO CONC2022/0008690A patent/CO2022008690A2/es unknown
- 2022-11-18 US US18/056,863 patent/US12448396B2/en active Active
-
2023
- 2023-03-27 JP JP2023049452A patent/JP7698676B2/ja active Active
- 2023-08-22 CL CL2023002486A patent/CL2023002486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| MX2023012725A (es) | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
| CO6300939A2 (es) | Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada | |
| UY31679A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| ECSP109953A (es) | Derivados de piridazinona | |
| NI201100137A (es) | Derivados de sulfonamida | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
| ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| UY31906A (es) | Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias. | |
| AR078613A1 (es) | Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. | |
| MX389244B (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer | |
| AR056049A1 (es) | 2-(2,6-dimetil-morfolin-4-il-n-[5-(6-morfolin-4-il-4-oxo-4h-piran-2-il)-9h-tioxanten-2-il]-acetamida,como inhibidor de la quinasa atm | |
| AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| UY38972A (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| CL2025002366A1 (es) | Compuesto que contiene trifluorometilsulfonilo. | |
| CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 |